NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat mental ...
The last time I spoke about Mind Medicine (MNMD) it was gearing up to report results from its phase 2b trial using its lead drug MM-120 for the treatment of patients with generalized anxiety disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback